Insurer Centene sues US over downgrade in Medicare 'star' rating
By Brendan Pierson
Oct 22 (Reuters) -Health insurance company Centene CNC.N accused U.S. regulators of unfairly downgrading the star ratings for its government-funded Medicare plans in a lawsuit on Tuesday.
The company alleged in its complaint, filed in St. Louis, Missouri, federal court, that the lower ratings would cause it to lose customers and up to $73 million in gross revenue, which could be used to reduce premiums and increase benefits for its members.
Centene offers so-called Medicare Advantage plans, which are funded by the Medicare health insurance program for seniors and some disabled people but administered by private insurers.
The U.S. Centers for Medicare and Medicaid Services (CMS) issues star ratings, from one to five stars, for Medicare Advantage plans, to help beneficiaries choose their plans. Plans with higher star ratings may also receive higher payments from the government if they keep costs below certain targets.
Centene said in the lawsuit that CMS docked its scores for the newest star ratings announced this month because of a single failed attempt to connect to its call center through a text-to-voice teletypewriter device. Such devices are used by people who are hard of hearing.
The St. Louis-based company said that, according to notes kept by the "secret shopper" employed by CMS to test the service, the call failed because of a software problem on the caller's end.
As a result, Centene said, seven of its health plans received a lower overall star rating, and four received a lower rating for prescription drug coverage, known as Medicare Part D.
"These are staggering consequences for a single call that never connected to plaintiffs' call center because the CMS secret shopper's (teletypewriter) software 'closed unexpectedly,'" Centene said.
Centene is asking the court to order HHS to recalculate its star rating "immediately" without considering the disputed call.
Despite the rating drop for some plans that Centene described in its lawsuit, the company said in an Oct. 11 disclosure that it had made "meaningful progress" overall in its 2025 ratings. It said that 46% of its Medicare Advantage members were enrolled in plans with star ratings of 3.5 star or higher, up from 23% in the previous year.
Humana HUM.N and UnitedHealth UNH.N filed similar lawsuits against CMS, challenging ratings downgrades earlier this month and also alleging that they were unfairly penalized for call center tests.
The case is Centene Corp et al v. Becerra, U.S. District Court for the Eastern District of Missouri, No. 4:24-cv-01415.
For Centene: Catherine Hanaway of Husch Blackwell
For HHS: not available
Read more:
US health agency releases 2025 quality ratings for Medicare plans
(Reporting By Brendan Pierson in New York)
</body></html>Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
